Pyrukynd

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
05-12-2022
Summary of Product characteristics Summary of Product characteristics (SPC)
05-12-2022
Public Assessment Report Public Assessment Report (PAR)
05-12-2022

Active ingredient:

mitapivat sulfate

Available from:

Agios Netherlands B.V.

ATC code:

B06AX04

INN (International Name):

mitapivat

Therapeutic group:

Other hematological agents

Therapeutic area:

Genetic Diseases, Inborn; Anemia, Hemolytic

Therapeutic indications:

Pyrukynd is indicated for the treatment of pyruvate kinase deficiency (PK deficiency) in adult patients (see section 4.

Authorization status:

упълномощен

Authorization date:

2022-11-09

Patient Information leaflet

                                59
Б. ЛИСТОВКА
60
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПАЦИЕНТА
PYRUKYND 5 MG ФИЛМИРАНИ ТАБЛЕТКИ
PYRUKYND 20 MG ФИЛМИРАНИ ТАБЛЕТКИ
PYRUKYND 50 MG ФИЛМИРАНИ ТАБЛЕТКИ
митапиват (mitapivat)
Това лекарство подлежи на
допълнително наблюдение. Това ще
позволи бързото
установяване на нова информация
относно безопасността. Можете да
дадете своя принос като
съобщите всяка нежелана реакция,
която сте получили. За начина на
съобщаване на нежелани
реакции вижте края на точка 4.
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА,
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ПРИЕМАТЕ ТОВА
ЛЕКАРСТВО,
ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
–
Запазете тази листовка. Може да се
наложи да я прочетете отново.
–
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар,
фармацевт или
медицинска сестра.
–
Това лекарство е предписано лично на
Вас. Не го преотстъпвайте на други
хора. То може
да им навреди, независимо че
признаците на тяхното заболяване са
същите като Вашите.
–
Ако получите някакви нежелани
лекарствени реакции, уведомете Вашия
лекар,
фармацевт или медицинска сестра. Това
включва всички възможни нежелани
реакции,
неописани в тази листовка. Вижте точка
4.
КАКВО СЪДЪРЖА ТАЗИ ЛИ
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
Този лекарствен продукт подлежи на
допълнително наблюдение. Това ще
позволи бързото
установяване на нова информация
относно безопасността. От
медицинските специалисти се
изисква да съобщават всяка подозирана
нежелана реакция. За начина на
съобщаване на
нежелани реакции вижте точка 4.8.
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Pyrukynd 5 mg филмирани таблетки
Pyrukynd 20 mg филмирани таблетки
Pyrukynd 50 mg филмирани таблетки
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Pyrukynd 5 mg филмирани таблетки
Всяка филмирана таблетка съдържа 5 mg
митапиват (mitapivat) (под формата на
сулфат).
_Помощно вещество с известно действие
_
Всяка филмирана таблетка съдържа 0,3 mg
лактоза (под формата на монохидрат).
Pyrukynd 20 mg филмирани таблетки
Всяка филмирана таблетка съдържа 20 mg
митапиват (mitapivat) (под формата на
сулфат).
_Помощно вещество с известно действие
_
Всяка филмирана таблетка съдържа 1,4 mg
лактоза (под формата на монохидрат).
Pyrukynd 50 mg филмирани таблетки
Всяка филмирана таблетка съдържа 50 mg
митапиват (под формата на сулфат).
_Помощно вещество с известно действие
_
Всяка филмирана таблетка съдържа 3,4 mg
лактоза (под формата н
                                
                                Read the complete document

Similar products

Active ingredient mitapivat sulfate

mitapivat sulfate

ATC code B06AX04

B06AX04

Marketed by Agios Netherlands B.V.

Agios Netherlands B.V.

INN (International Name) mitapivat

mitapivat

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 05-12-2022
Summary of Product characteristics Summary of Product characteristics Spanish 05-12-2022
Public Assessment Report Public Assessment Report Spanish 05-12-2022
Patient Information leaflet Patient Information leaflet Czech 05-12-2022
Summary of Product characteristics Summary of Product characteristics Czech 05-12-2022
Public Assessment Report Public Assessment Report Czech 05-12-2022
Patient Information leaflet Patient Information leaflet Danish 05-12-2022
Summary of Product characteristics Summary of Product characteristics Danish 05-12-2022
Public Assessment Report Public Assessment Report Danish 05-12-2022
Patient Information leaflet Patient Information leaflet German 05-12-2022
Summary of Product characteristics Summary of Product characteristics German 05-12-2022
Public Assessment Report Public Assessment Report German 05-12-2022
Patient Information leaflet Patient Information leaflet Estonian 05-12-2022
Summary of Product characteristics Summary of Product characteristics Estonian 05-12-2022
Public Assessment Report Public Assessment Report Estonian 05-12-2022
Patient Information leaflet Patient Information leaflet Greek 05-12-2022
Summary of Product characteristics Summary of Product characteristics Greek 05-12-2022
Public Assessment Report Public Assessment Report Greek 05-12-2022
Patient Information leaflet Patient Information leaflet English 05-12-2022
Summary of Product characteristics Summary of Product characteristics English 05-12-2022
Public Assessment Report Public Assessment Report English 05-12-2022
Patient Information leaflet Patient Information leaflet French 05-12-2022
Summary of Product characteristics Summary of Product characteristics French 05-12-2022
Public Assessment Report Public Assessment Report French 05-12-2022
Patient Information leaflet Patient Information leaflet Italian 05-12-2022
Summary of Product characteristics Summary of Product characteristics Italian 05-12-2022
Public Assessment Report Public Assessment Report Italian 05-12-2022
Patient Information leaflet Patient Information leaflet Latvian 05-12-2022
Summary of Product characteristics Summary of Product characteristics Latvian 05-12-2022
Public Assessment Report Public Assessment Report Latvian 05-12-2022
Patient Information leaflet Patient Information leaflet Lithuanian 05-12-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 05-12-2022
Public Assessment Report Public Assessment Report Lithuanian 05-12-2022
Patient Information leaflet Patient Information leaflet Hungarian 05-12-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 05-12-2022
Public Assessment Report Public Assessment Report Hungarian 05-12-2022
Patient Information leaflet Patient Information leaflet Maltese 05-12-2022
Summary of Product characteristics Summary of Product characteristics Maltese 05-12-2022
Public Assessment Report Public Assessment Report Maltese 05-12-2022
Patient Information leaflet Patient Information leaflet Dutch 05-12-2022
Summary of Product characteristics Summary of Product characteristics Dutch 05-12-2022
Public Assessment Report Public Assessment Report Dutch 05-12-2022
Patient Information leaflet Patient Information leaflet Polish 05-12-2022
Summary of Product characteristics Summary of Product characteristics Polish 05-12-2022
Public Assessment Report Public Assessment Report Polish 05-12-2022
Patient Information leaflet Patient Information leaflet Portuguese 05-12-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 05-12-2022
Public Assessment Report Public Assessment Report Portuguese 05-12-2022
Patient Information leaflet Patient Information leaflet Romanian 05-12-2022
Summary of Product characteristics Summary of Product characteristics Romanian 05-12-2022
Public Assessment Report Public Assessment Report Romanian 05-12-2022
Patient Information leaflet Patient Information leaflet Slovak 05-12-2022
Summary of Product characteristics Summary of Product characteristics Slovak 05-12-2022
Public Assessment Report Public Assessment Report Slovak 05-12-2022
Patient Information leaflet Patient Information leaflet Slovenian 05-12-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 05-12-2022
Public Assessment Report Public Assessment Report Slovenian 05-12-2022
Patient Information leaflet Patient Information leaflet Finnish 05-12-2022
Summary of Product characteristics Summary of Product characteristics Finnish 05-12-2022
Public Assessment Report Public Assessment Report Finnish 05-12-2022
Patient Information leaflet Patient Information leaflet Swedish 05-12-2022
Summary of Product characteristics Summary of Product characteristics Swedish 05-12-2022
Public Assessment Report Public Assessment Report Swedish 05-12-2022
Patient Information leaflet Patient Information leaflet Norwegian 05-12-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 05-12-2022
Patient Information leaflet Patient Information leaflet Icelandic 05-12-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 05-12-2022
Patient Information leaflet Patient Information leaflet Croatian 05-12-2022
Summary of Product characteristics Summary of Product characteristics Croatian 05-12-2022
Public Assessment Report Public Assessment Report Croatian 05-12-2022
Patient Information leaflet Patient Information leaflet Irish 05-12-2022
Summary of Product characteristics Summary of Product characteristics Irish 05-12-2022

Search alerts related to this product

Alerts Pyrukynd mitapivat sulfate

Pyrukynd mitapivat sulfate

View documents history

Documents history Documents history

Pyrukynd